Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.37 |
| ▸ | SORD | Q00796 | 6/20 | 0.36 |
| ▸ | RBP4 | P02753 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745395 | 1.00 | DYRK1A (0.39) | DYRK1ANR1H2HCRTR2HCRTR1SORD | |
| SCHEMBL20745400 | 0.85 | HCRTR2 (0.39) | NR1H2HCRTR2HCRTR1SORD | |
| SCHEMBL20745392 | 0.83 | NR1H2 (0.40) | DYRK1ANR1H2HCRTR2HCRTR1SORD | |
| SCHEMBL20745270 | 0.77 | NR1H2 (0.39) | DYRK1ANR1H2HCRTR2HCRTR1SORD | |
| SCHEMBL31434276 | 0.77 | SORD (0.41) | NR1H2HCRTR2HCRTR1SORD | |
| SCHEMBL20745096 | 0.77 | NR1H2 (0.39) | NR1H2HCRTR2HCRTR1SORDRBP4 | |
| SCHEMBL20745976 | 0.77 | ACACB (0.43) | NR1H2HCRTR2HCRTR1SORD | |
| SCHEMBL16815392 | 0.75 | PIK3CA (0.51) | SORD | |
| SCHEMBL22320481 | 0.74 | NR1H2 (0.39) | NR1H2HCRTR2HCRTR1SORD | |
| SCHEMBL20745928 | 0.74 | NR1H2 (0.39) | NR1H2HCRTR2HCRTR1SORDRBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3668502-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019035927-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | DYRK1A 2584/4885NR1H2 3568/4885HCRTR2 4683/4885 |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | DYRK1A 2584/4885NR1H2 3568/4885HCRTR2 4683/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | DYRK1A 2584/4885NR1H2 3568/4885HCRTR2 4683/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | DYRK1A 2584/4885NR1H2 3568/4885HCRTR2 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.